Poster Session : PS 1421 ; Hemato-Oncology(Hematology) : Posterior Reversible Encephalopathy Syndrome As-sociated with FOLFIRI Chemotherapy in Metastatic Colorectal Cacer: A Case Report = Poster Session : PS 1421 ; Hemato-Oncology(Hematology) : Posterior Reversible Encephalopathy Syndrome As-sociated with FOLFIRI Chemotherapy in Metastatic Colorectal Cacer: A Case Report

다국어 초록 (Multilingual Abstract)

Background: Posterior reversible encephalopathy syndrome (PRES) is known to have symptoms of headache, visual disturbances, altered consciouseness and seizures, which can be result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES ocurred as a result of FOLfiRI (irinotecan, 5-FU) chemotherapy in metastatic colorectal cacer/ Case Report: A 51-year old male with diagnosed of rectal cancer with liver metastasis, underwent an a low anterior resection on April,19, 2013.After operation, he has XELOX (capecitabine, oxaliplatin) as palliative chemotherapy. After sixth XELOX chemotherapy, chemotherapy as change of disease progression. When FOLfiRI chemotherapy administered, suddenly he appeared to have partial seizure with sudden eyeball deviation . The infusion of chemotherapy was stopped immediately ,he had treatment with anticonvulsants, such as phenytoin, levetiracetam. The brain MRI showed that white matter change in the bilateral occipital lobe, supported the diagnosis of PRES. The conservative treatment was continued for several days. After few days, the patient recovered from symptom and after that, he had chemotherapy XELOX and bevacizumab instead of FOLfiRI. The brain MRI after six months did not show any previous lesion, he is currently well being followed up as an outpatient. Conclusion: There are no known reports of the association between PRES and FOLfiRI chemotherapy.We postulate that FOLfiRI chemotherapy can disrupt the normal endothelial function of the brain leading to the development of PRES.